Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 295


Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial.

Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M.

JAMA. 2004 Feb 4;291(5):565-75.


Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial.

Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM; Veterans Affairs Site Investigators.

JAMA. 2007 Sep 12;298(10):1163-70. Erratum in: JAMA. 2008 Jul 9;300(2):170.


Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial.

Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, Buring JE, Manson JE.

JAMA. 2008 May 7;299(17):2027-36. doi: 10.1001/jama.299.17.2027.


Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial.

Ebbing M, Bleie Ø, Ueland PM, Nordrehaug JE, Nilsen DW, Vollset SE, Refsum H, Pedersen EK, Nygård O.

JAMA. 2008 Aug 20;300(7):795-804. doi: 10.1001/jama.300.7.795.


The China Stroke Secondary Prevention Trial (CSSPT) protocol: a double-blinded, randomized, controlled trial of combined folic acid and B vitamins for secondary prevention of stroke.

Liu X, Shi M, Xia F, Han J, Liu Z, Wang B, Yang F, Li L, Wu S, Wang L, Liu N, Lv Y, Zhao G.

Int J Stroke. 2015 Feb;10(2):264-8. doi: 10.1111/ijs.12017. Epub 2013 Mar 12.


Homocysteine lowering and cardiovascular events after acute myocardial infarction.

Bønaa KH, Njølstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, Wang H, Nordrehaug JE, Arnesen E, Rasmussen K; NORVIT Trial Investigators.

N Engl J Med. 2006 Apr 13;354(15):1578-88. Epub 2006 Mar 12.


Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial.

Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group, Armitage JM, Bowman L, Clarke RJ, Wallendszus K, Bulbulia R, Rahimi K, Haynes R, Parish S, Sleight P, Peto R, Collins R.

JAMA. 2010 Jun 23;303(24):2486-94. doi: 10.1001/jama.2010.840.


Homocysteine-lowering therapy and risk of recurrent stroke, myocardial infarction and death: the impact of age in the VISP trial.

Towfighi A, Arshi B, Markovic D, Ovbiagele B.

Cerebrovasc Dis. 2014;37(4):263-7. doi: 10.1159/000360153. Epub 2014 Apr 15.


Homocysteine lowering with folic acid and B vitamins in vascular disease.

Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J Jr; Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators.

N Engl J Med. 2006 Apr 13;354(15):1567-77. Epub 2006 Mar 12. Erratum in: N Engl J Med. 2006 Aug 17;355(7):746.


Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE)-2 trial.

Lonn E, Held C, Arnold JM, Probstfield J, McQueen M, Micks M, Pogue J, Sheridan P, Bosch J, Genest J, Yusuf S; HOPE-2 Investigators.

Can J Cardiol. 2006 Jan;22(1):47-53.


Plasma Abeta, homocysteine, and cognition: the Vitamin Intervention for Stroke Prevention (VISP) trial.

Viswanathan A, Raj S, Greenberg SM, Stampfer M, Campbell S, Hyman BT, Irizarry MC.

Neurology. 2009 Jan 20;72(3):268-72. doi: 10.1212/01.wnl.0000339486.63862.db.


Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial.

Hankey GJ, Eikelboom JW, Yi Q, Lees KR, Chen C, Xavier D, Navarro JC, Ranawaka UK, Uddin W, Ricci S, Gommans J, Schmidt R; VITATOPS trial study group.

Lancet Neurol. 2012 Jun;11(6):512-20. doi: 10.1016/S1474-4422(12)70091-1. Epub 2012 May 2.


Vitamin Intervention for Stroke Prevention (VISP) trial: rationale and design.

Spence JD, Howard VJ, Chambless LE, Malinow MR, Pettigrew LC, Stampfer M, Toole JF.

Neuroepidemiology. 2001 Feb;20(1):16-25.


Impact and interaction of low estimated GFR and B vitamin therapy on prognosis among ischemic stroke patients: the Vitamin Intervention for Stroke Prevention (VISP) trial.

Lee M, Markovic D, Ovbiagele B.

Am J Kidney Dis. 2013 Jul;62(1):52-7. doi: 10.1053/j.ajkd.2013.02.355. Epub 2013 Apr 6.


Vitamin Intervention For Stroke Prevention trial: an efficacy analysis.

Spence JD, Bang H, Chambless LE, Stampfer MJ.

Stroke. 2005 Nov;36(11):2404-9. Epub 2005 Oct 20.


Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial.

Saposnik G, Ray JG, Sheridan P, McQueen M, Lonn E; Heart Outcomes Prevention Evaluation 2 Investigators.

Stroke. 2009 Apr;40(4):1365-72. doi: 10.1161/STROKEAHA.108.529503. Epub 2009 Feb 19.


Sustained homocysteine-lowering effect over time of folic acid-based multivitamin therapy in stroke patients despite increasing folate status in the population.

Hankey GJ, Eikelboom JW, Loh K, Tang M, Pizzi J, Thom J, Yi Q.

Cerebrovasc Dis. 2005;19(2):110-6. Epub 2004 Dec 17.

Items per page

Supplemental Content

Write to the Help Desk